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Genomic profiling of lower-grade 
gliomas uncovers cohesive disease groups: 
implications for diagnosis and treatment
Chang‑Ming Zhang1,2* and Daniel J. Brat2*
Abstract 
Lower‑grade gliomas (including low‑ and intermediate‑grade gliomas, World Health Organization grades II and III) 
are diffusely infiltrative neoplasms that arise most often in the cerebral hemispheres of adults and have traditionally 
been classified based on their presumed histogenesis as astrocytomas, oligodendrogliomas, or oligoastrocytomas. 
Although the histopathologic classification of lower‑grade glioma has been the accepted standard for nearly a 
century, it suffers from high intra‑ and inter‑observer variability and does not adequately predict clinical outcomes. 
Based on integrated analysis of multiplatform genomic data from The Cancer Genome Atlas, lower‑grade gliomas 
have been found to segregate into three cohesive, clinically relevant molecular classes. Molecular classes were closely 
aligned with the status of isocitrate dehydrogenase (IDH) mutations, tumor protein 53 mutations and the co‑deletion 
of chromosome arms 1p and 19q, but were not closely aligned with histologic classes. These findings emphasize the 
potential for improved definition of clinically relevant disease subsets using integrated molecular approaches and 
highlight the importance of biomarkers for brain tumor classification.
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Background
Diffuse low-grade and intermediate-grade gliomas 
[World Health Organization (WHO) grades II and III, 
hereafter called lower-grade gliomas] are infiltrative neo-
plasms that arise most often in the cerebral hemispheres 
of adults [1, 2]. Histologic criteria for the diagnosis of 
diffuse gliomas date from the early 20th century work 
of Bailey and Cushing [3], who grouped tumors by their 
presumed histogenesis based on their appearance under 
the microscope (i.e., classes were based on their “cell of 
origin”). Since then, histologic diagnosis has remained an 
efficient and cost-effective method for classification and 
grading, serving as the international standard [2]. Using 
these methods, lower-grade gliomas have traditionally 
been categorized into three classes: oligodendrogliomas, 
astrocytomas, and oligoastrocytomas. Following clas-
sification, diffuse gliomas are graded II–IV based on the 
presence of other morphologic features that reflect bio-
logical behavior, such as mitosis, microvascular prolifera-
tion, and necrosis, in order to predict clinical outcome 
and guide patient management. Despite widespread 
acceptance for nearly a century, it has been recognized 
that histologic classification and grading suffer from sub-
stantial inter- and intra-observer variability and do not 
adequately predict clinical outcomes [4, 5].
Increasingly, biomarker-based classification has been 
used to categorize disease and guide clinical decision 
making [6, 7]. For example, isocitrate dehydrogenase 
(IDH) mutations have been shown to be associated with 
a favorable prognosis in diffuse gliomas. The finding of 
co-deletion of chromosome arms 1p and 19q (1p/19q 
co-deletion) has been strongly linked with the oligo-
dendroglioma histology and predicts better responses 
to radiochemotherapy. In order to determine if robust, 
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clinically meaningful molecular classes of lower-grade 
gliomas could be identified and recognized by specific 
biomarkers, The Cancer Genome Atlas (TCGA) recently 
performed a comprehensive and integrated molecu-
lar analysis [8]. In their study, 293 untreated diffuse 
lower-grade glioma samples were collected from adults, 
including 100 astrocytomas, 77 oligoastrocytomas, and 
116 oligodendrogliomas [8]. A comprehensive molecu-
lar analysis was performed for mutations using whole-
exome sequencing, DNA copy number alterations, DNA 
methylation, microRNA expression, mRNA expression, 
and targeted protein expression. The results were inte-
grated by two independent, multiplatform methods: 
cluster of clusters (CoC), which integrated data from 
gene expression (mRNA), DNA methylation, miRNA 
expression, and copy number alteration platforms; and 
OncoSign, which integrated mutations, amplifications, 
and deletions.
These two independent and unsupervised analyses each 
pointed to three robust molecular classes of lower-grade 
gliomas. Investigators then compared these three molec-
ular classes to histologic classification of gliomas and to 
the biomarker classification of lower-grade glioma based 
on the status of IDH mutation and 1p/19q co-deletion. 
For both the CoC and OncoSign analyses, the associa-
tion between molecular class and IDH–1p/19q co-dele-
tion status was far superior to the association between 
molecular class and histologic class, indicating that these 
biomarkers were capable of accurately capturing cohe-
sive biological characteristics of lower-grade gliomas in 
a robust manner. Based on these studies, lower-grade 
gliomas were designated as either (1) IDH mutant with 
1p/19q co-deletion; (2) IDH mutant without 1p/19q co-
deletion; or (3) IDH wild-type.
The first subtype of lower-grade gliomas, characterized 
by both IDH mutations and 1p/19q co-deletion, showed a 
strong association with the oligodendroglioma histologic 
class, consistent with the results of numerous studies 
which emphasized that the combination of IDH muta-
tion and 1p/19q co-deletion is the molecular signature 
of this disease (Fig. 1) [9]. Other findings in this subtype 
included activating mutations of the telomerase reverse 
transcriptase (TERT) promoter in nearly all cases (96%) 
[10]. Other frequent mutations were noted in capicua 
transcriptional repressor (CIC), neurogenic locus notch 
homolog protein 1 (NOTCH1), far upstream element-
binding protein 1 (FUBP1), and the PI3 kinase pathway 
gene phosphatidylinositol-4, 5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA). Of note, this subset 
was associated with the most favorable clinical outcomes, 
with a median patient survival of 8.0 years, partially due 
to the well-recognized radiochemosensitivity of tumors 
with 1p/19q co-deletion.
The second subtype of lower-grade gliomas had IDH 
mutations but lacked 1p/19q co-deletion and TERT pro-
moter mutations (Fig. 1). Instead, they were characterized 
by mutations or losses of alpha thalassemia/mental retar-
dation syndrome X-linked (ATRX) and tumor protein 
p53 (TP53) in 86 and 94% of cases, respectively. Thus, 
in IDH-mutant lower-grade gliomas, a strong, mutually 
exclusive relationship exists between TP53 mutations and 
1p/19q co-deletions. IDH-mutant lower-grade gliomas 
have either one or the other of these molecular events, 
but rarely both, indicating a strict molecular dichotomy. 
Lower-grade gliomas with IDH, TP53, and ATRX altera-
tions have the molecular signature of diffuse astrocytoma 
and a median patient survival of 6.3 years [11].
The third molecular subtype of lower-grade gliomas 
had wild-type IDH and displayed a range of genetic alter-
ations completely distinct from those of IDH-mutant 
lower-grade gliomas (Fig. 1). Genetic alterations in IDH 
wild-type tumors showed a remarkable resemblance to 
primary glioblastoma (WHO grade IV) across all ana-
lytic platforms [including genetic aberrations in phos-
phatase and tensin homolog (PTEN), neurofibromin 1 
(NF1), cyclin-dependent kinase inhibitor 2A (CDKN2A), 
TP53 regulator (MDM4), TERT promoter, and epidermal 
growth factor receptor (EGFR)]. Both the genomic prop-
erties and clinical behavior suggested that IDH wild-type 
lower-grade gliomas are immediate precursors to IDH 
wide-type glioblastoma.
This unsupervised analysis of genome-wide molecular 
data identified three robust disease categories that can be 
recognized using well-established biomarkers, including 
IDH, 1p/19q, TP53, ATRX, and TERT. Importantly, these 
molecularly defined subsets are cohesive and reproduc-
ible, whereas histologic classes, by themselves, are not. 













Activating: EGFR, TERT 
Fig. 1 Schematic representation of diffuse glioma molecular clas‑
sification. Lower‑grade gliomas, the diffuse low‑grade and interme‑
diate‑grade gliomas (World Health Organization grades II and III), are 
divided into three cohesive molecular subtypes based on molecular 
markers, including isocitrate dehydrogenase (IDH) mutations, co‑
deletion of chromosome arms 1p and 19q (1p/19q co‑deletion), and 
tumor protein p53 (TP53)
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For example, tumors diagnosed as “oligoastrocytoma” 
were found in all three molecular classes and lacked a 
defining molecular signature. Previously, diagnostic cri-
teria for oligoastrocytomas have been inconsistent, and 
many lower-grade gliomas with “ambiguous morphol-
ogy” have been treated as oligoastrocytomas [12]. Results 
indicated that lower-grade gliomas with an IDH muta-
tion have either 1p/19q co-deletion or a TP53 mutation, 
reflecting two distinct molecular mechanisms of onco-
genesis; furthermore, no evidence exists for a biological 
or genetic signature specific to oligoastrocytoma. Based 
on these findings and others, molecular markers can be 
used to determine lineage rather than histologic appear-
ance, and the proportion of “oligoastrocytoma” diagnosis 
among lower-grade gliomas will likely decrease.
Ultimately, the studies by TCGA indicate that advances 
in molecular profiling will allow neoplastic diseases to 
be defined using a new approach. Unsupervised clus-
tering of whole-genome molecular data has ushered in 
a new age in which biological classes of disease can be 
precisely identified. In the case of lower-grade gliomas, 
well-established genetic markers (such as IDH, 1p/19q, 
ATRX, TP53, and TERT) were capable of identifying new 
disease classes with high fidelity. In histologic classifica-
tion, ambiguous morphology is common, resulting in low 
reproducibility and inter-observer concordance, leading 
to confusion in clinical management. Molecular classifi-
cation represents an improvement in diagnostic practice, 
enabling practitioners to identify clinically distinct neo-
plasms and confidently direct appropriate standard ther-
apies or clinical trials.
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